Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19)
Scope of the Report
The report titled “Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses key opportunities in the market and outlines the factors that are and will be driving growth of the industry. Growth of the overall CHC industry has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. An insight into strategic issues affecting key brands on the market is provided followed by an analysis of the leading companies in the hormonal contraceptives market. The report also analyzes the key CHC products in pipeline.Further, key players of the industry like Agile Therapeutics; Bayer Healthcare; Teva Pharmaceuticals and Actavis PLC; are analyzed in the report.
Country Coverage
Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring.
Most popular Combined Hormonal Contraceptives products are Nuvaring and Ortho Evra. CHC products are broadly used throughout the world by women in the age-group of 15 to 49 years. With increasing health consciousness and awareness, adoption of CHC products or birth control methods is increasing in lesser privileged economic segments too. The growth of CHC market is driven by urbanization and increasing user awareness, rise in menstruating population globally and initiatives taken by governments to encourage the use of contraception. Major trends prevailing in the market are the increasing number of mergers and acquisitions in this business space and demand for reversible method of contraception with fewer side effects.
The report titled “Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)” provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses key opportunities in the market and outlines the factors that are and will be driving growth of the industry. Growth of the overall CHC industry has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. An insight into strategic issues affecting key brands on the market is provided followed by an analysis of the leading companies in the hormonal contraceptives market. The report also analyzes the key CHC products in pipeline.Further, key players of the industry like Agile Therapeutics; Bayer Healthcare; Teva Pharmaceuticals and Actavis PLC; are analyzed in the report.
Country Coverage
- United states
- United Kingdom
- India
- China
- Japan
- Agile Therapeutics Inc.
- Actavis Plc.
- Bayer Healthcare
- Teva Pharmaceuticals
Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring.
Most popular Combined Hormonal Contraceptives products are Nuvaring and Ortho Evra. CHC products are broadly used throughout the world by women in the age-group of 15 to 49 years. With increasing health consciousness and awareness, adoption of CHC products or birth control methods is increasing in lesser privileged economic segments too. The growth of CHC market is driven by urbanization and increasing user awareness, rise in menstruating population globally and initiatives taken by governments to encourage the use of contraception. Major trends prevailing in the market are the increasing number of mergers and acquisitions in this business space and demand for reversible method of contraception with fewer side effects.
1. EXECUTIVE SUMMARY
2. COMBINED HORMONAL CONTRACEPTIVES MARKET: AN OVERVIEW
2.1 Definition
2.2 History
2.3 Classification
2.3.1 Combined Oral Contraceptive Pills
2.3.2 Combined Vaginal Rings
2.3.3 Combined Transdermal Patches
2.3.4 Combined Injectable Birth Control
2.3.5 Combined Emergency Contraceptive Pills
2.4 Mechanism of Action
2.5 Components of CHCs
2.6 Advantages of Combined Hormonal Contraceptives
2.7 Disadvantages of Combined Hormonal Contraceptives
2.8 Contraindications
2.9 Serious Risks
3. COMBINED HORMONAL CONTRACEPTIVES(CHC) MARKET ANALYSIS
3.1 Global CHC Market Sizing and Growth
3.2 Global CHC Market Breakup: Branded vs. Generic
3.3 CHC Generic Market
3.4 Global CHC Branded Market
4. COMBINED HORMONAL CONTRACEPTIVES(CHC): MARKET SHARE ANALYSIS
4.1 Global CHC Market Share by Class
4.2 Global CHC Market Share by Key Players
4.3 Global CHC Market Share by Key Products
5. COMBINED HORMONAL CONTRACEPTIVES(CHC): COUNTRY ANALYSIS
5.1 The U.S. Combined Hormonal Contraceptives Market
5.2 The UK Combined Hormonal Contraceptives Market
5.3 Japan Combined Hormonal Contraceptives Market
5.4 India Combined Hormonal Contraceptives Market
5.5 China Combined Hormonal Contraceptives Market
6. MARKET DYNAMICS: COMBINED HORMONAL CONTRACEPTIVES(CHC) MARKET
6.1 Growth Drivers
6.1.1 Rise in Healthcare Expenditure
6.1.2 Growth in the U.S. Contraceptive Market
6.1.3 Government Initiatives
6.1.4 The Prescriber Base is Easily Targeted
6.2 Challenges
6.2.1 Strict Regulatory Compliance
6.2.2 Serious Adverse Events
6.3 Market Trends
6.3.1 Significant M&A activity in Women’s Health Market
6.3.2 Use of Newer Progestins
7. COMPETITIVE LANDSCAPE: COMBINED HORMONAL CONTRACEPTIVES(CHC) MARKET
8. COMPANY PROFILES: COMBINED HORMONAL CONTRACEPTIVES(CHC) MARKET
8.1 Agile therapeutics, Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Actavis Plc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Bayer Healthcare
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 Teva Pharmaceutical Industries Limited
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategies
2. COMBINED HORMONAL CONTRACEPTIVES MARKET: AN OVERVIEW
2.1 Definition
2.2 History
2.3 Classification
2.3.1 Combined Oral Contraceptive Pills
2.3.2 Combined Vaginal Rings
2.3.3 Combined Transdermal Patches
2.3.4 Combined Injectable Birth Control
2.3.5 Combined Emergency Contraceptive Pills
2.4 Mechanism of Action
2.5 Components of CHCs
2.6 Advantages of Combined Hormonal Contraceptives
2.7 Disadvantages of Combined Hormonal Contraceptives
2.8 Contraindications
2.9 Serious Risks
3. COMBINED HORMONAL CONTRACEPTIVES(CHC) MARKET ANALYSIS
3.1 Global CHC Market Sizing and Growth
3.2 Global CHC Market Breakup: Branded vs. Generic
3.3 CHC Generic Market
3.4 Global CHC Branded Market
4. COMBINED HORMONAL CONTRACEPTIVES(CHC): MARKET SHARE ANALYSIS
4.1 Global CHC Market Share by Class
4.2 Global CHC Market Share by Key Players
4.3 Global CHC Market Share by Key Products
5. COMBINED HORMONAL CONTRACEPTIVES(CHC): COUNTRY ANALYSIS
5.1 The U.S. Combined Hormonal Contraceptives Market
5.2 The UK Combined Hormonal Contraceptives Market
5.3 Japan Combined Hormonal Contraceptives Market
5.4 India Combined Hormonal Contraceptives Market
5.5 China Combined Hormonal Contraceptives Market
6. MARKET DYNAMICS: COMBINED HORMONAL CONTRACEPTIVES(CHC) MARKET
6.1 Growth Drivers
6.1.1 Rise in Healthcare Expenditure
6.1.2 Growth in the U.S. Contraceptive Market
6.1.3 Government Initiatives
6.1.4 The Prescriber Base is Easily Targeted
6.2 Challenges
6.2.1 Strict Regulatory Compliance
6.2.2 Serious Adverse Events
6.3 Market Trends
6.3.1 Significant M&A activity in Women’s Health Market
6.3.2 Use of Newer Progestins
7. COMPETITIVE LANDSCAPE: COMBINED HORMONAL CONTRACEPTIVES(CHC) MARKET
8. COMPANY PROFILES: COMBINED HORMONAL CONTRACEPTIVES(CHC) MARKET
8.1 Agile therapeutics, Inc.
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Actavis Plc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Bayer Healthcare
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 Teva Pharmaceutical Industries Limited
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategies
LIST OF FIGURES AND TABLES
Figure 1: Types of Combined Hormonal Contraceptives
Figure 2: Fixed Dose Microgynon® 30 ED
Figure 3: Combined Vaginal Rings
Figure 4: Twirla Patch Components
Figure 5: Mechanism of Action
Figure 6: Annual Sales of Global CHC Market; 2008-2013 (US$ Million)
Figure 7: Global CHC Market Size by Annual Sales Forecasted; 2014-2019E (US$ Million)
Figure 8: Global CHC Market Breakup: Branded vs. Generic
Figure 9: Annual Sales of Global Generic CHC Market; 2008-2013 (US$ Million)
Figure 10: Annual Sales of Global Branded CHC Market; 2008-2013 (US$ Million)
Figure 11: Global CHC Market Share by Class; 2013
Figure 12: Global CHC Market Share by Key Players; 2013
Figure 13: Global CHC Market Share by Key Products; 2013
Figure 14: Women Population Aged 15-49 years in Seven Major Markets; 2013 (Thousands)
Figure 15: Women Population Aged 15-49 years in Seven Major Market taking Hormonal contraception by class; 2010-2013 (Thousands)
Figure 16: Women Population Aged 15-49 years in Seven Major Market taking Hormonal Contraception Forecasted; 2014-2019 (Thousands)
Table 1: Key Oral Contraceptives (OC) TRx (million)
Figure 17: U.S. Oral Contraceptive TRx Breakdown; 2013 (US$ 4 billion)
Figure 18: U.S. Oral Contraceptive Sales Breakdown; 2013 (US$ 4 billion)
Figure 19: Indian versus MNC generic’s TRx share; 2013
Figure 20: Healthcare Expenditure Worldwide; 2007-2013 (US$ Million)
Figure 21: Population - Women aged 15-44 years in the US: 2008-2020 (Thousands)
Figure 22: US CHC Market -Quarterly Prescription Growth (%)
Table 2: Leading Players of Hormonal Contraceptives Market
Table 3: Hormonal Contraception Market: Key Players and their Marketed Products and Pipeline Products
Figure 23: Global Sales of Key Products: FY 2013 (US$ Million)
Figure 24: Twirla Patch Components
Figure 25: Skinfusion Technology
Table 4: Agile Therapeutics Product Pipeline
Figure 26: Agile Net Revenue Forecasted: 2016-2021 (US$ Million)
Figure27: Actavis Plc. Net Revenue (consolidated): 2009-12 (US$ Million)
Figure 28: Actavis specialty brand; Net Revenue and Product Sales (consolidated): 2012-13 (US$ Million)
Figure 29: Bayer Pharmaceuticals, Net Sales: 2010-13 (US$ Billion)
Figure 30: YAZ/Yashmin/Yasminelle, Net sales: 2010-13 (US$ Million)
Figure 31: Teva Specialty Medicines Net Revenue by Region: 2013 (US$ Billion)
Figure 32: Teva Women Health Products Net Revenue: FY 2011-13 (US$ Million)
Figure 1: Types of Combined Hormonal Contraceptives
Figure 2: Fixed Dose Microgynon® 30 ED
Figure 3: Combined Vaginal Rings
Figure 4: Twirla Patch Components
Figure 5: Mechanism of Action
Figure 6: Annual Sales of Global CHC Market; 2008-2013 (US$ Million)
Figure 7: Global CHC Market Size by Annual Sales Forecasted; 2014-2019E (US$ Million)
Figure 8: Global CHC Market Breakup: Branded vs. Generic
Figure 9: Annual Sales of Global Generic CHC Market; 2008-2013 (US$ Million)
Figure 10: Annual Sales of Global Branded CHC Market; 2008-2013 (US$ Million)
Figure 11: Global CHC Market Share by Class; 2013
Figure 12: Global CHC Market Share by Key Players; 2013
Figure 13: Global CHC Market Share by Key Products; 2013
Figure 14: Women Population Aged 15-49 years in Seven Major Markets; 2013 (Thousands)
Figure 15: Women Population Aged 15-49 years in Seven Major Market taking Hormonal contraception by class; 2010-2013 (Thousands)
Figure 16: Women Population Aged 15-49 years in Seven Major Market taking Hormonal Contraception Forecasted; 2014-2019 (Thousands)
Table 1: Key Oral Contraceptives (OC) TRx (million)
Figure 17: U.S. Oral Contraceptive TRx Breakdown; 2013 (US$ 4 billion)
Figure 18: U.S. Oral Contraceptive Sales Breakdown; 2013 (US$ 4 billion)
Figure 19: Indian versus MNC generic’s TRx share; 2013
Figure 20: Healthcare Expenditure Worldwide; 2007-2013 (US$ Million)
Figure 21: Population - Women aged 15-44 years in the US: 2008-2020 (Thousands)
Figure 22: US CHC Market -Quarterly Prescription Growth (%)
Table 2: Leading Players of Hormonal Contraceptives Market
Table 3: Hormonal Contraception Market: Key Players and their Marketed Products and Pipeline Products
Figure 23: Global Sales of Key Products: FY 2013 (US$ Million)
Figure 24: Twirla Patch Components
Figure 25: Skinfusion Technology
Table 4: Agile Therapeutics Product Pipeline
Figure 26: Agile Net Revenue Forecasted: 2016-2021 (US$ Million)
Figure27: Actavis Plc. Net Revenue (consolidated): 2009-12 (US$ Million)
Figure 28: Actavis specialty brand; Net Revenue and Product Sales (consolidated): 2012-13 (US$ Million)
Figure 29: Bayer Pharmaceuticals, Net Sales: 2010-13 (US$ Billion)
Figure 30: YAZ/Yashmin/Yasminelle, Net sales: 2010-13 (US$ Million)
Figure 31: Teva Specialty Medicines Net Revenue by Region: 2013 (US$ Billion)
Figure 32: Teva Women Health Products Net Revenue: FY 2011-13 (US$ Million)
